Study says abatacept and adalimumab offer comparable benefits in RA
Clinical outcomes of ABA and ADA treatments were comparable in an RA patient cohort.
Subcutaneous abatacept (ABA) and adalimumab (ADA) provide comparable benefits and safety levels in patients with the chronic inflammatory disease rheumatoid arthritis (RA).
This is according to findings from a two-year head-to-head biologics clinical trial AMPLE, which were presented at EULAR 2013 - Annual European Congress of Rheumatology event.
Researchers recruited 646 patients affected by the autoimmune disease into an experiment and randomly assigned them into the ABA or ADA group.
Lead author Dr Michael Schiff, of the University of Colorado, and colleagues analysed the results and found that patient outcomes were similar at one and two years.
He said: "This robust data set demonstrates that subcutaneous abatacept and adalimumab are equally efficacious in clinical, functional and radiographic outcomes."
Safety levels were also comparable, with results showing that rates of adverse events and serious adverse events varied little, between 13.8 per cent (ABA) and 16.5 per cent (ADA).
The findings could provide doctors with more options when it comes to treating RA, which affects an estimated 21 million people worldwide, seriously compromising quality of life.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance